NEXTPOINT THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nextpointtx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- NextPoint Therapeutics, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT06240728
- Locations
- 🇺🇸
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
🇺🇸Albert Einstein Medical College Montefiore Medical Center, Bronx, New York, United States
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- NextPoint Therapeutics, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT05958199
- Locations
- 🇺🇸
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Albert Einstein Medical College Montefiore Medical Center, New York, New York, United States
News
No news found